256 related articles for article (PubMed ID: 21278242)
1. A phase I study of the heat shock protein 90 inhibitor alvespimycin (17-DMAG) given intravenously to patients with advanced solid tumors.
Pacey S; Wilson RH; Walton M; Eatock MM; Hardcastle A; Zetterlund A; Arkenau HT; Moreno-Farre J; Banerji U; Roels B; Peachey H; Aherne W; de Bono JS; Raynaud F; Workman P; Judson I
Clin Cancer Res; 2011 Mar; 17(6):1561-70. PubMed ID: 21278242
[TBL] [Abstract][Full Text] [Related]
2. Phase I trial of 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG), a heat shock protein inhibitor, administered twice weekly in patients with advanced malignancies.
Kummar S; Gutierrez ME; Gardner ER; Chen X; Figg WD; Zajac-Kaye M; Chen M; Steinberg SM; Muir CA; Yancey MA; Horneffer YR; Juwara L; Melillo G; Ivy SP; Merino M; Neckers L; Steeg PS; Conley BA; Giaccone G; Doroshow JH; Murgo AJ
Eur J Cancer; 2010 Jan; 46(2):340-7. PubMed ID: 19945858
[TBL] [Abstract][Full Text] [Related]
3. A phase I dose-escalation trial of trastuzumab and alvespimycin hydrochloride (KOS-1022; 17 DMAG) in the treatment of advanced solid tumors.
Jhaveri K; Miller K; Rosen L; Schneider B; Chap L; Hannah A; Zhong Z; Ma W; Hudis C; Modi S
Clin Cancer Res; 2012 Sep; 18(18):5090-8. PubMed ID: 22781552
[TBL] [Abstract][Full Text] [Related]
4. Phase I study of the heat shock protein 90 inhibitor alvespimycin (KOS-1022, 17-DMAG) administered intravenously twice weekly to patients with acute myeloid leukemia.
Lancet JE; Gojo I; Burton M; Quinn M; Tighe SM; Kersey K; Zhong Z; Albitar MX; Bhalla K; Hannah AL; Baer MR
Leukemia; 2010 Apr; 24(4):699-705. PubMed ID: 20111068
[TBL] [Abstract][Full Text] [Related]
5. Phase I pharmacokinetic and pharmacodynamic study of 17-dimethylaminoethylamino-17-demethoxygeldanamycin, an inhibitor of heat-shock protein 90, in patients with advanced solid tumors.
Ramanathan RK; Egorin MJ; Erlichman C; Remick SC; Ramalingam SS; Naret C; Holleran JL; TenEyck CJ; Ivy SP; Belani CP
J Clin Oncol; 2010 Mar; 28(9):1520-6. PubMed ID: 20177028
[TBL] [Abstract][Full Text] [Related]
6. Phase I study of 17-allylamino-17 demethoxygeldanamycin, gemcitabine and/or cisplatin in patients with refractory solid tumors.
Hubbard J; Erlichman C; Toft DO; Qin R; Stensgard BA; Felten S; Ten Eyck C; Batzel G; Ivy SP; Haluska P
Invest New Drugs; 2011 Jun; 29(3):473-80. PubMed ID: 20082116
[TBL] [Abstract][Full Text] [Related]
7. Co-treatment with heat shock protein 90 inhibitor 17-dimethylaminoethylamino-17-demethoxygeldanamycin (DMAG) and vorinostat: a highly active combination against human mantle cell lymphoma (MCL) cells.
Rao R; Lee P; Fiskus W; Yang Y; Joshi R; Wang Y; Buckley K; Balusu R; Chen J; Koul S; Joshi A; Upadhyay S; Tao J; Sotomayor E; Bhalla KN
Cancer Biol Ther; 2009 Jul; 8(13):1273-80. PubMed ID: 19440035
[TBL] [Abstract][Full Text] [Related]
8. Open-label, dose-escalation, safety, pharmacokinetic, and pharmacodynamic study of intravenously administered CNF1010 (17-(allylamino)-17-demethoxygeldanamycin [17-AAG]) in patients with solid tumors.
Saif MW; Erlichman C; Dragovich T; Mendelson D; Toft D; Burrows F; Storgard C; Von Hoff D
Cancer Chemother Pharmacol; 2013 May; 71(5):1345-55. PubMed ID: 23564374
[TBL] [Abstract][Full Text] [Related]
9. Phase I pharmacokinetic-pharmacodynamic study of 17-(allylamino)-17-demethoxygeldanamycin (17AAG, NSC 330507), a novel inhibitor of heat shock protein 90, in patients with refractory advanced cancers.
Ramanathan RK; Trump DL; Eiseman JL; Belani CP; Agarwala SS; Zuhowski EG; Lan J; Potter DM; Ivy SP; Ramalingam S; Brufsky AM; Wong MK; Tutchko S; Egorin MJ
Clin Cancer Res; 2005 May; 11(9):3385-91. PubMed ID: 15867239
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of Hsp90 inhibition for induction of apoptosis and inhibition of growth in cervical carcinoma cells in vitro and in vivo.
Schwock J; Pham NA; Cao MP; Hedley DW
Cancer Chemother Pharmacol; 2008 Apr; 61(4):669-81. PubMed ID: 17579866
[TBL] [Abstract][Full Text] [Related]
11. Phase I pharmacokinetic and pharmacodynamic study of LAQ824, a hydroxamate histone deacetylase inhibitor with a heat shock protein-90 inhibitory profile, in patients with advanced solid tumors.
de Bono JS; Kristeleit R; Tolcher A; Fong P; Pacey S; Karavasilis V; Mita M; Shaw H; Workman P; Kaye S; Rowinsky EK; Aherne W; Atadja P; Scott JW; Patnaik A
Clin Cancer Res; 2008 Oct; 14(20):6663-73. PubMed ID: 18927309
[TBL] [Abstract][Full Text] [Related]
12. First-in-human phase I dose escalation study of a second-generation non-ansamycin HSP90 inhibitor, AT13387, in patients with advanced solid tumors.
Shapiro GI; Kwak E; Dezube BJ; Yule M; Ayrton J; Lyons J; Mahadevan D
Clin Cancer Res; 2015 Jan; 21(1):87-97. PubMed ID: 25336693
[TBL] [Abstract][Full Text] [Related]
13. Stage 1 testing and pharmacodynamic evaluation of the HSP90 inhibitor alvespimycin (17-DMAG, KOS-1022) by the pediatric preclinical testing program.
Smith MA; Morton CL; Phelps DA; Kolb EA; Lock R; Carol H; Reynolds CP; Maris JM; Keir ST; Wu J; Houghton PJ
Pediatr Blood Cancer; 2008 Jul; 51(1):34-41. PubMed ID: 18260120
[TBL] [Abstract][Full Text] [Related]
14. A phase 1 dose-escalation study of irinotecan in combination with 17-allylamino-17-demethoxygeldanamycin in patients with solid tumors.
Tse AN; Klimstra DS; Gonen M; Shah M; Sheikh T; Sikorski R; Carvajal R; Mui J; Tipian C; O'Reilly E; Chung K; Maki R; Lefkowitz R; Brown K; Manova-Todorova K; Wu N; Egorin MJ; Kelsen D; Schwartz GK
Clin Cancer Res; 2008 Oct; 14(20):6704-11. PubMed ID: 18927314
[TBL] [Abstract][Full Text] [Related]
15. 17-DMAG induces heat shock protein 90 functional impairment in human bladder cancer cells: knocking down the hallmark traits of malignancy.
Karkoulis PK; Stravopodis DJ; Voutsinas GE
Tumour Biol; 2016 May; 37(5):6861-73. PubMed ID: 26662567
[TBL] [Abstract][Full Text] [Related]
16. Monitoring therapeutic response of human ovarian cancer to 17-DMAG by noninvasive PET imaging with (64)Cu-DOTA-trastuzumab.
Niu G; Li Z; Cao Q; Chen X
Eur J Nucl Med Mol Imaging; 2009 Sep; 36(9):1510-9. PubMed ID: 19440708
[TBL] [Abstract][Full Text] [Related]
17. Hypoxia attenuates Hsp90 inhibitor 17-DMAG-induced cyclin B1 accumulation in hepatocellular carcinoma cells.
Zhang J; Li H; Huang Z; He Y; Zhou X; Huang T; Dai P; Duan D; Ma X; Yin Q; Wang X; Liu H; Chen S; Zou F; Chen X
Cell Stress Chaperones; 2016 Mar; 21(2):339-48. PubMed ID: 26786409
[TBL] [Abstract][Full Text] [Related]
18. Schedule-dependent synergy between the heat shock protein 90 inhibitor 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin and doxorubicin restores apoptosis to p53-mutant lymphoma cell lines.
Robles AI; Wright MH; Gandhi B; Feis SS; Hanigan CL; Wiestner A; Varticovski L
Clin Cancer Res; 2006 Nov; 12(21):6547-56. PubMed ID: 17085670
[TBL] [Abstract][Full Text] [Related]
19. Phase I trial of 17-allylamino-17-demethoxygeldanamycin in patients with advanced cancer.
Goetz MP; Toft D; Reid J; Ames M; Stensgard B; Safgren S; Adjei AA; Sloan J; Atherton P; Vasile V; Salazaar S; Adjei A; Croghan G; Erlichman C
J Clin Oncol; 2005 Feb; 23(6):1078-87. PubMed ID: 15718306
[TBL] [Abstract][Full Text] [Related]
20. The apoptotic effect and associated signalling of HSP90 inhibitor 17-DMAG in hepatocellular carcinoma cells.
Leng AM; Liu T; Yang J; Cui JF; Li XH; Zhu YN; Xiong T; Zhang G; Chen Y
Cell Biol Int; 2012 Oct; 36(10):893-9. PubMed ID: 22694478
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
